Lai M, McCormick J A, Chapman K E, Kelly P A T, Seckl J R, Yau J L W
Endocrinology Unit, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK.
Neuroscience. 2003;118(4):975-84. doi: 10.1016/s0306-4522(03)00038-1.
Hyperactivity of the hypothalamic-pituitary-adrenal axis is a characteristic feature of depressive illness. The centrally located corticosteroid receptors, the glucocorticoid and mineralocorticoid receptors, are thought to be important modulators of this axis and changes in the levels of these receptors, particularly in the hippocampus, may underlie the hyperactivity observed. Various antidepressant drugs increase hippocampal mineralocorticoid and glucocorticoid receptor levels in vivo. These effects are thought to be mediated via alterations in monoaminergic neurotransmission. We examined whether serotonin (5HT) and noradrenaline (NA) have direct effects on glucocorticoid receptor and mineralocorticoid receptor expression in primary hippocampal neurones, and whether antidepressants also exert direct effects on target neurones. Exposure of hippocampal cells to 5HT for 4 days increased both glucocorticoid and mineralocorticoid receptor mRNA and protein expression. The induction of mineralocorticoid receptor mRNA was completely blocked by the 5HT(7) receptor antagonist SB 269970. In contrast glucocorticoid receptor induction was insensitive to the 5HT(7) receptor, whilst studies with the 5HT(1A) receptor agonist 8-hydroxy-2-(di-n-proplamino) tetralin hydrochloride and the 5HT(1A) receptor antagonist N-[2-[4-2-[O-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane carboxamide trihydrochloride (WAY 100635) suggest a partial role for 5HT(1A) receptors in hippocampal glucocorticoid receptor regulation. Treatment with NA for 4 days also increased glucocorticoid receptor expression but had no effect on mineralocorticoid receptor expression. This was blocked by propanolol suggesting action via beta-adrenergic receptors. Similarly to NA, fluoxetine and amitriptyline also selectively increased glucocorticoid receptor mRNA and protein levels over this time course. However, glucocorticoid receptor induction by fluoxetine or amitriptyline was not blocked by WAY 100635 or propanolol. These results show that 5HT, NA and antidepressants act directly but via distinct mechanisms on hippocampal neurones to regulate mineralocorticoid and glucocorticoid receptor expression. Thusly, manipulation of neurotransmitter or antidepressant levels in the brain may aid in reversing hypothalamic-pituitary-adrenal axis hyperactivity by restoring hippocampal corticosteroid receptor balance.
下丘脑-垂体-肾上腺轴功能亢进是抑郁症的一个特征性表现。位于中枢的皮质类固醇受体,即糖皮质激素受体和盐皮质激素受体,被认为是该轴的重要调节因子,这些受体水平的变化,尤其是海马体中的变化,可能是观察到的功能亢进的基础。各种抗抑郁药物可在体内增加海马体盐皮质激素和糖皮质激素受体水平。这些作用被认为是通过单胺能神经传递的改变介导的。我们研究了血清素(5HT)和去甲肾上腺素(NA)是否对原代海马神经元中糖皮质激素受体和盐皮质激素受体的表达有直接影响,以及抗抑郁药物是否也对靶神经元有直接作用。将海马细胞暴露于5HT 4天可增加糖皮质激素和盐皮质激素受体的mRNA及蛋白表达。5HT(7)受体拮抗剂SB 269970可完全阻断盐皮质激素受体mRNA的诱导。相反,糖皮质激素受体的诱导对5HT(7)受体不敏感,而使用5HT(1A)受体激动剂盐酸8-羟基-2-(二正丙氨基)四氢萘和5HT(1A)受体拮抗剂N-[2-[4-2-(邻甲氧基苯基)-1-哌嗪基]乙基]-N-(2-吡啶基)环己烷甲酰胺三盐酸盐(WAY 100635)的研究表明,5HT(1A)受体在海马糖皮质激素受体调节中起部分作用。用NA处理4天也可增加糖皮质激素受体表达,但对盐皮质激素受体表达无影响。这被普萘洛尔阻断,提示其通过β-肾上腺素能受体起作用。与NA类似,氟西汀和阿米替林在这段时间内也选择性地增加了糖皮质激素受体的mRNA和蛋白水平。然而,氟西汀或阿米替林诱导的糖皮质激素受体增加并未被WAY 100635或普萘洛尔阻断。这些结果表明,5HT、NA和抗抑郁药物通过不同机制直接作用于海马神经元,以调节盐皮质激素和糖皮质激素受体表达。因此,通过恢复海马皮质类固醇受体平衡,调节大脑中的神经递质或抗抑郁药物水平可能有助于逆转下丘脑-垂体-肾上腺轴功能亢进。